Qualify defined, serum-free media for StemSight's manufacturing process
Moving iPSC-derived cells to the clinic requires defined, low-variability media; Defined Bioscience sells exactly this for pluripotent stem cells. A supply and co-development agreement lowers StemSight's cost of goods and gives Defined Bioscience a clinical-pathway customer.
Evidence from the records
- “Fully defined media formulations with stabilized growth factors, reducing the cost and variability of stem cell culture.”
- “Corneal cells derived from induced pluripotent stem cells (iPS); clinical trials targeted around 2027.”
- “patent granted in Singapore (June 2026) for its scalable stem cell technology.”
- If it works
- Lower manufacturing cost and a qualified supplier for the clinical process.
- First step
- Request HiDef-B8 samples and run a comparison against current media.
